Workflow
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of useMore than half of the nearly 9 million people in the United States with plaque psoriasis experience scalp involvementHealthcare providers and individuals with plaque psoriasis can now choose ZORYVE foam or cream to treat plaque psoriasis anywhere it appears on the bodyFifth FDA approval for ZORYVE in less than three yearsManagement will host an investor event with a key opinion lead ...